22 the hypothesis that intensification and prolongation of remission induction produce a higher percentage of disease-free long-term survivors [2] . We decided in 1981 to adopt a modified BFM protocol for ALL therapy in our group [3] . This paper presents preliminary results of this multicenter randomized study.
B. Materials and Methods

I. Patients
A total of 208 consecutive, previously untreated children with ALL were entered in- 100  60  5  1112  5  5  4  5  31  23  12  79  59  23  5  5/12  5  54  41  37  4  10/12  5  11  8  34  2  2  20   o   7   5  4  2  10  7  2  15 11 37 spleen enlargement: standard (SR), medium (MR), and high risk (HR) groups [4] .
to the study (VlII81) between September 1981 and March 1984. Patients' character-II. Treatment istics are given in Table 1 . Patients were divided into three risk groups according to the initial leukocyte count and liver and sisting of two phases, was identical for each risk group. The reinforced reinduction protocols were risk adjusted: protocol III for SR, protocol II for MR, and protocol IV for HR patients. For prophylactic CNS therapy in the SR group, patients were randomized to receive cranial irradiation and intrathecal methotrexate (MTX) or medium dose methotrexate (500 mg/m2) and intrathecal methotrexate (Fig. I) . For the duration of maintenance therapy, patients were randomized after 78 weeks to receive MTX and 6-MP for another 6 months or protocol III. The induction therapy of the BFM scheme was modified by reducing L-asparaginase in dose and duration. The reinduction with protocol III before stopping therapy was the second modification to the BFM protocol.
III. Statistical Analysis
Complete remission (CR) was defined as less than 5 % bone marrow and no evidence of extramedullary leukemia. Kaplan-Meier analysis were performed for survival and continuous CR. Failure is defined as induction failure, initial relapse at any site, death during induction, or death during initial CR.
c. Results
Preliminary results are summarized in Table 2 . It was found that 93% of patients attained CR after 4 weeks of therapy. The cumulative proportion in continuous CR is 0.77 ± 0.04 for the total group of 195 patients (Fig. 6) . No significant difference was found between the treatment groups SR (0.83 ± 0.04) and MR (0.78 ± 0.07) (Fig. 7) . Of 14 HR patients, 11 (79%) attained CR. One died in CR and four relapsed (three bone marrow relapses, one CNS relapse). Thus, the proportion in continuous CR was 0.19 ± 0.16. Of the total number of children, 12 relapsed. Eight patients had isolated marrow relapse. Isolated CNS rela pses occurred in two children. One patient had a simultaneous marrow and CNS relapse and one patient had an isolated relapse in the eye. Patients with the BFM group that intensification and prolongation of remission induction produce a higher percentage of disease-free long-term survivors [2, 5] . Patients in the HR group (risk factor > 1.7) did worse than those in the SR and MR groups. This is in marked contrast to the results reported by the BFM group [5] .
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